X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
TEVA PHARMA
Dec-13
SUN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs7012,912-   
Low Rs4332,530-   
Sales per share (Unadj.) Rs110.41,671.4-  
Earnings per share (Unadj.) Rs11.0104.4-  
Cash flow per share (Unadj.) Rs17.2239.5-  
Dividends per share (Unadj.) Rs2.0091.40-  
Dividend yield (eoy) %0.43.4 10.5%  
Book value per share (Unadj.) Rs158.81,856.6-  
Shares outstanding (eoy) m2,399.26848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.6 315.4%   
Avg P/E ratio x51.626.1 198.1%  
P/CF ratio (eoy) x32.911.4 289.6%  
Price / Book Value ratio x3.61.5 243.6%  
Dividend payout %18.287.5 20.8%   
Avg Mkt Cap Rs m1,360,0212,307,433 58.9%   
No. of employees `00017.844.9 39.6%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.931,534.3 47.2%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.61,969.9 75.2%   
INCOME DATA
Net Sales Rs m264,8951,417,308 18.7%  
Other income Rs m8,3880-   
Total revenues Rs m273,2821,417,308 19.3%   
Gross profit Rs m56,081388,131 14.4%  
Depreciation Rs m14,998114,562 13.1%   
Interest Rs m5,17627,838 18.6%   
Profit before tax Rs m44,295245,730 18.0%   
Minority Interest Rs m01,116 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505-161,308 5.9%   
Tax Rs m8,452-3,000 -281.7%   
Profit after tax Rs m26,33888,538 29.7%  
Gross profit margin %21.227.4 77.3%  
Effective tax rate %19.1-1.2 -1,562.9%   
Net profit margin %9.96.2 159.2%  
BALANCE SHEET DATA
Current assets Rs m316,359957,244 33.0%   
Current liabilities Rs m198,643834,798 23.8%   
Net working cap to sales %44.48.6 514.4%  
Current ratio x1.61.1 138.9%  
Inventory Days Days9591 104.4%  
Debtors Days Days10896 112.3%  
Net fixed assets Rs m213,178462,924 46.1%   
Share capital Rs m2,3993,489 68.8%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,0061,574,360 24.2%   
Long term debt Rs m17,721724,701 2.4%   
Total assets Rs m643,0283,239,002 19.9%  
Interest coverage x9.69.8 97.3%   
Debt to equity ratio x00.5 10.1%  
Sales to assets ratio x0.40.4 94.1%   
Return on assets %4.93.6 136.4%  
Return on equity %6.95.6 122.9%  
Return on capital %10.04.9 203.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,072225,845 17.3%  
From Investments Rs m-33,708-80,026 42.1%  
From Financial Activity Rs m-15,393-270,917 5.7%  
Net Cashflow Rs m-7,359-125,098 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.77 Rs / USD

Compare SUN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SUN PHARMA With: STERLING BIOTECH  NATCO PHARMA  SANOFI INDIA  STRIDES PHARMA SCIENCE  VENUS REMEDIES  



Today's Market

Sensex Ends 382 Points Lower; Auto and Telecom Stocks Witness Selling(Closing)

India share markets witnessed huge selling pressure during closing hours and ended their trading session deep in the red.

Related Views On News

NSE Nifty at All Time High; HDFC Among Top Gainers (Market Updates)

May 21, 2019 | Updated on May 21, 2019

Markets all time high analysis : The nse index at all time high; HDFC among top gainers. Find the latest update, special reports and news on all time high gainers of NSE Index at equitymaster.com.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 21, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PANACEA BIOTECH COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS